Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:approves |
gptkb:2022
gptkb:European_Union gptkb:United_States |
| gptkbp:can_be_combined_with |
gptkb:durvalumab
|
| gptkbp:clinical_trial |
Phase 3
NCT02477696 NCT02834013 NCT02834026 NCT02834039 NCT02834052 NCT02834065 NCT02834078 NCT02834091 NCT02834104 NCT02834117 |
| gptkbp:developed_by |
gptkb:Astra_Zeneca
|
| https://www.w3.org/2000/01/rdf-schema#label |
tremelimumab
|
| gptkbp:indication |
gptkb:Oncology
gptkb:malignant_melanoma |
| gptkbp:marketed_as |
gptkb:Imfinzi
|
| gptkbp:mechanism_of_action |
immune checkpoint inhibition
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:side_effect |
immune-related adverse events
|
| gptkbp:targets |
gptkb:CTLA-4
|
| gptkbp:type |
gptkb:immunotherapy
|
| gptkbp:used_for |
gptkb:cancer_treatment
|
| gptkbp:bfsParent |
gptkb:Durvalumab
gptkb:James_P._Allison |
| gptkbp:bfsLayer |
6
|